The study is withdrawn due to strategic reasons.

This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance using a computer program, so neither participants nor study staff will know which treatment is given. The study will last for about one year.

Inclusion Criteria:

• Male or female (sex at birth)
• Age 18 years or above at the time of signing the informing consent.
• Body Mass Index (BMI) is greater than or equal to (>= ) 30.0 kilograms per square metre (kg/m^2) or BMI >= 27.0 kg/m^2 with the presence of at least one obesity-related complication including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

Exclusion Criteria:

• Glycosylated haemoglobin (HbA1c) >= 6.5 % (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
• History of type 1 or type 2 diabetes.
• Previous exposure to CagriSema in a clinical study.

According to the Novo Nordisk disclosure commitment on novonordisktrials.com

Sponsor staff involved in the clinical trial is masked according to company standard procedures.